BRTX-100

A Novel Treatment for Chronic Lower Back Pain

Each year, over 25 million Americans suffer from chronic lower back pain — half of them with degenerative disc disease. Traditional treatments manage symptoms but fail to address the root cause, leaving many to pursue risky and often ineffective surgery.

BRTX-100 offers a new path forward. This innovative, single-injection therapy uses the patient’s own stem cells to directly target and begin repairing damaged intervertebral discs. With FDA authorization for a Phase 2 clinical trial, BRTX-100 has the potential to transform the treatment of chronic lumbar disc disease (cLDD).

The Science Behind BRTX-100

Autologous Cell-Based Biologic

Uses the patient’s own bone marrow-derived stem cells, minimizing the risk of rejection or complications

Hypoxic Culturing Process

Grown in low-oxygen conditions to enhance cell proliferation, survival, and regenerative potential

Platelet Lysate Enhanced

Supplemented with growth factors to support healing and improve outcomes

Streamlined Procedure

Single intradiscal injection, designed as a ~30-minute, in-office treatment

WHY IT MATTERS

The cLDD Market
0
M
U.S. adults with chronic lower back pain
0
M
Diagnosed with and treated for disc degeneration
0
M
Experiencing pain from a protruding or injured disc
0
M
Undergoing invasive spinal surgeries each year
$
0
B
Annual cost of spinal surgeries in the U.S.
* Trinity Partners Report, “Degenerative Disc Disease US Market Assessment (Phase I),” Feb. 2016, Slide 9 of report.